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Abstract
Background: The concomitant incidence of cancer and pregnancy has increased in recent years because of the increase in
maternal age at the time of the 1st pregnancy. The diagnosis of cancer in a pregnant woman causes ethical and therapeutic problems
for both the patient and the physician. Themain aim of this paper is to describe the available evidence concerning the short- and long-
term neonatal impact of chemotherapy given to pregnant women.
Methods:The relevant publications in English were identiﬁed by a systematic review of MEDLINE and PubMed for the last 15 years.
The search strategy included “cancer[Title/Abstract] OR tumor[Title/Abstract] AND pregnancy[Title/Abstract] OR pregnant[Title/
Abstract] AND embryo[Title/Abstract] or fetus[Title/Abstract] or neonate[Title/Abstract] or newborn[Title/Abstract] or pediatric[Title/
Abstract] or child[Title/Abstract] AND English[lang].”
Results:An analysis of the literature showed that only the administration of chemotherapy during the embryonic stage of conceptus
is dangerous and can lead to the termination of the pregnancy. When the disease is diagnosed in the 2nd or 3rd trimester of gestation
or when it is possible to delay the initiation of chemotherapy beyond the 14th week, the risk of severe problems for the fetus are low,
and pregnancy termination is not required.
Conclusion: Data regarding the ﬁnal outcome of children who have received in utero chemotherapy seem reassuring. Only the
administration in the embryonal stage of conceptus is dangerous and can lead to the termination of pregnancy. When the disease is
diagnosed in the 2nd or 3rd trimester of gestation or when it is possible to delay the initiation of chemotherapy beyond the 14th week,
the risk of severe problems for the fetus are low and pregnancy termination is not needed. Increased knowledge of how to minimize
the risks of chemotherapy can reduce improper management including unnecessary termination of pregnancy, delayed maternal
treatment, and iatrogenic preterm delivery.
Keywords: cancer, chemotherapy, children, embryo, fetus, neonate, pregnancy1. Introduction
The concomitant incidence of cancer and pregnancy is a rare
event and is estimated to account for only 1 to 2 cases per 1000
pregnancies. However, the numbers have increased in recent
years because of the increase in maternal age at the time of the 1st
pregnancy.[1–3] The most common tumors diagnosed during
pregnancy are the same that are common in females ofEditor: Giovanni Li Volti.
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1childbearing age and include breast cancer, cervical cancer,
leukemia, lymphoma, and lung cancer (Table 1).[4] Breast cancer
is the most common form of cancer diagnosed during pregnancy
and occurs in 1 to 3 cases per 10,000 pregnancies. Diagnosis is
frequently delayed during pregnancy because some symptoms,
including breast enlargement and changes in breast texture, are
initially considered physiological manifestations of pregnancy,
which makes diagnosis of cancer-related breast changes difﬁcult
to detect.[5] Rarely, routine procedures performed during
pregnancy can uncover cancer. A Pap test, when performed as
part of standard pregnancy care, can also detect cervical cancer,
and an ultrasound, when performed to monitor fetal develop-
ment, can also detect ovarian cancer.
The diagnosis of cancer in pregnant women causes ethical and
therapeutic problems for both the patient and the physician.
Most of the problems arise from the treatment options and in
particular, from chemotherapy. Pregnant women with cancer
tend to abstain from treatment for the fear of fetal damage.
Conversely, physicians have to balance embryo and fetal well-
being with maternal prognosis, taking in account that, even if
rarely, vertical transmission of cancer can occur and the child can
suffer of the same disease of the mother.[6] To reduce the risk of
damage, it is important to understand the optimum use of
cytotoxic drugs in pregnant women.[7] Unfortunately, this
knowledge is lacking in the ﬁeld, and the time course for therapy
initiation, the appropriate drug choice, and the total daily dose
and fractioning have not been clearly established. It is well known
that physiological changes in pregnancy can signiﬁcantly affect
drug disposition, especially in the 2nd and 3rd trimester of
Table 1




Commonly used chemotherapy alone or in association
with other treatments
Breast cancer 10–30 Neoadjuvant chemotherapy is based on taxanes (paclitaxel or docetaxel)
In advanced/metastatic settings, anthracycline-based regimes (daunorubicin, doxorubicin, epirubicin,
idarubicin, and valrubicin) or taxanes are the drugs of choice
Hematologic malignancies Lymphoma 10–60 For Hodgkin lymphoma, vincristine can be used as single agent until after delivery. If combination
therapy is needed, adriamycin, bleomycin, vinblastine, and dacarbazine are prescribed. For
indolent non-Hodgkin lymphoma, chemotherapy is not administered in the 1st phases of disease:
if drugs are needed, chlorambucil as single-agent or combination with cyclophosphamide,
vincristine, and prednisone is given with or without rituximab
Leukemia 1 Remission induction is performed with cytarabine and an anthracycline (daunorubicin or idarubicin),
consolidation is obtained with high-dose cytarabine
Cervical cancer 10 Noninvasive carcinoma: treatment is deferred to the postpartum period
Invasive carcinoma: surgery is of choice and neoadjuvant chemotherapy with platinum analogs
(carboplatin or cisplatin) has been suggested
Ovarian cancer 10 Low malignant potential types do not require chemotherapy
Epithelial ovarian cancer is given platinum analogs with or without a taxane
Germ cell tumors receive bleomycin, etoposide, and cisplatin combined regimen
Thyroid cancer 3.6–14 Chemotherapy is not prescribed. Surgery and hormonal therapy are the treatments of choice
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pregnant women has only been deﬁned for some anticancer drugs
but not for other drugs that are effective in certain types of
tumors.[8] The decision of whether and how to administer
chemotherapy could be improved by data regarding the ﬁnal
outcome of children born to mothers with cancer who were
adequately treated during pregnancy; however, data are limited
and are mainly derived from retrospective case series or reports.
Therefore, the main aim of this paper is to describe the available
evidence concerning the short- and long-term impact of
chemotherapy given to pregnant women with cancer on the
neonate.
2. Methods
The relevant publications in English were identiﬁed by a
systematic review of MEDLINE and PubMed for the last 15
years. The search strategy included “cancer[Title/Abstract] OR
tumor[Title/Abstract] AND pregnancy[Title/Abstract] OR preg-
nant[Title/Abstract] AND embryo[Title/Abstract] or fetus[Title/
Abstract] or neonate[Title/Abstract] or newborn[Title/Abstract]
or pediatric[Title/Abstract] or child[Title/Abstract] AND English
[lang].” Randomized controlled trials, prospective/retrospective
studies, and case reports in the English language were included. If
the article was not published in English, we relied on the abstract
as it appeared in the search engine. No authors declared conﬂict
of interest. Ethics Committee approval was not requested because
it is not needed for systematic reviews of the literature according
to the Israeli and Italian laws.
3. Results
3.1. The impact of chemotherapy on the embryo and fetus
The effects of chemotherapy on the conceptus depends on several
factors, including the duration and timing of the exposure, the
dose of the drugs that reaches the embryo or the fetus, and the
modalities with which they interfere with cell metabolism.[9]
Older-generation alkylators (i.e., procarbazine, busulfan, chlor-
ambucil, and nitrogen mustard) and the antimetabolites
aminopterin and methotrexate have high teratogenic and2abortive potential; conversely, anthracyclines and vinca alkaloids
(i.e., vinblastine and vincristine) have lower fetotoxic poten-
tial.[10] The use of cytotoxic drugs during fertilization or
implantation (i.e., during the 1st 10 days after conception) can
lead to one of 2 opposite phenomena: the death of the embryo or
the proper development of the embryo. The 1st trimester is the
period during which the majority of organogenesis occurs and
chemotherapy can exert a signiﬁcant teratogenic effect, particu-
larly on the heart, limbs, palate, neural tube, eyes, and ears.[11]
Therefore, the administration of cytotoxic drugs during the 1st
trimester is particularly dangerous because it is frequently
associated with the development of malformations, embryo
death, and spontaneous abortion. The risk of malformations is
approximately 7% to 17% when a single agent treatment is used
and increases to 25% in cases of combination therapy.[12] The
strict association between chemotherapy during the 1st 12 weeks
of gestation and the risk of malformations explains why experts
agree with the recommendation of delaying the initiation of
chemotherapy in pregnant women with cancer until after the end
of the 1st trimester of gestation.[13] Outside this period, the
inﬂuence of chemotherapy in fetal and child outcomes is
signiﬁcantly lower, and the risk of malformations has not been
explicitly demonstrated. Doll et al[14] reported major malforma-
tions in 1.3% of children born to mothers with cancer who had
been treated with chemotherapy after the 1st trimester, which is a
risk value similar to the general population without chemothera-
py treatment. Moreover, although it has been reported that the
eyes, genitalia, central nervous system, and hematopoietic
systems remain vulnerable to continued exposure to cytotoxic
drugs during the last months of gestation, and intrauterine
growth retardation is a possible complication of that expo-
sure,[15,16] several studies have shown that chemotherapy
administered during the 2nd or 3rd trimester of pregnancy has
little effect on the long-term outcome of the child, which favors its
use to control cancer in pregnant women.[17–19]
The relatively good tolerance of the fetus to maternal
chemotherapy is, at least in part, explained by the limited
exposure of the conceptus to the cytotoxic drugs compared to the
pregnant mother. Placental passage of a drug is a function of
multiple factors including protein binding, lipid solubility, and
Esposito et al. Medicine (2016) 95:38 www.md-journal.comionization constant; however, fetal exposure to drugs depends on
maternal pharmacokinetics including the volume of distribution,
the rate of metabolism and excretion by the placenta, the pH
difference between maternal and fetal ﬂuids, and the effect of
hemodynamic changes in the mother during pregnancy.[20] Many
drugs used to treat cancer have characteristics that favor passive
diffusion through the placenta because they have a lowmolecular
weight and are lipid-soluble and nonionized. Despite this, these
drugs typically reach in the fetal circulatory system at concen-
trations that are signiﬁcantly lower than those present in the
mother.[21] Several placental transporters (i.e., multidrug-resis-
tant proteins, P-glycoprotein, and breast cancer resistance
proteins) regulate the uptake and efﬂux of drugs used in
pregnancy to reduce the concentrations in fetal blood.[22]
Moreover, the absorption of drugs from the gastrointestinal
tract during pregnancy is modiﬁed because of changes in gastric
secretion and motility. Furthermore, maternal drug metabolism
may be altered due to the elevation of endogenous hormones such
as progesterone.[23,24] Finally, therapeutic concentrations of the
active drug may also be affected by hemodynamic changes that
take place throughout pregnancy. For example, blood volume
increases by 40% and total body water content increases by 5%
to 8%, due to the expansion of the extracellular ﬂuid space and
the growth of new tissue.[25] Body water also accumulates in the
fetus, placenta, and amniotic ﬂuid. This contributes to an increase
in volume of distribution and may lower the concentration of
drugs by increasing their elimination half-life. Realistically, all the
drugs used to treat cancer reach the fetus in a relatively low
concentration, although there are signiﬁcant differences among
the individual drugs. Observations in primates show the passage
can be marginal (paclitaxel, 0%–1%), hardly valuable (anthra-
cyclines, 5%–7%), or relatively high (carboplatin, 60%) depend-
ing on the drug assessed; however, the concentrations are always
signiﬁcantly lower compared to the mother.[26,27]
3.2. The impact of chemotherapy on pregnancy
Chemotherapy has been associated with an increased risk of
stillbirth and fetal growth restriction.[28,29] Van Calsteren et al[29]
detected a demonstrable increase in preterm delivery in pregnant
women exposed to cytotoxic therapy in comparison to healthy
unexposed women (4% vs 11.8%, P=0.01). However, a
deﬁnitive conclusion cannot be made because in some studies
no differences were detected in both the gestational age and birth
weight between children born to mothers with cancer receiving
chemotherapy and those born to healthy women.[30–34] Con-
versely, the occurrence of prematurity can cause relevant
problems; however, it is unclear whether these problems depend
on the drug administration or is linked to other factors related to
the disease itself.
3.3. The perinatal and long-term effects on children from
chemotherapy administered during pregnancy
3.3.1. Perinatal effects.At birth and in the 1st few weeks of life,
a number of children born to mothers treated with chemotherapy
present with transient myelosuppression, which involve leuko-
penia (white blood cell count <5000/mm3) and/or neutropenia
(absolute neutrophil count <1500/mm3) with anemia and/or
thrombocytopenia (platelet count <15,000/mm3).[35,36] More-
over, in children born to mothers treated with rituximab, a
monoclonal antibody against the protein CD20 used to treat B-
cell non-Hodgkin lymphoma, selective B-cell depletion was
observed.[35]3Generally, transient myelosuppression is maximally evident in
the 1st days of life and is resolved within 2 to 10 weeks. Its
frequency varies from 43% and 33% in the studies by Aviles and
Neri[34] and Reynoso et al,[28] respectively, to 4% observed by
Cardonick and Iacobucci[9] in a review of 321 published case
reports. Data from an international cancer and pregnancy
registry collected from 1995 to 2008 showed that among 157
neonates exposed to various chemotherapy drugs during
pregnancy, only 2 infants suffered from transient myelosup-
pression or anemia at birth, and neither suffered from
opportunistic infections.[35] These differences may have several
explanations, including the different therapeutic regimens.
However, the most important reason may be the timing of
therapy suspension with respect to the timing of childbirth;
speciﬁcally, when treatment is maintained until the end of
pregnancy, the risk of transient myelosuppression is signiﬁcantly
higher whereas the risk is greatly reduced the more extensive time
period between the suspension of chemotherapy and childbirth.
For this reason, it is recommended that delivery is avoided during
the maternal nadir period, and chemotherapy should not be
administered after the 35th week of gestation in order to allow
the fetus to eliminate the cytotoxic drugs.[36] Theoretically,
transient myelosuppression might lead to severe infections, and
systematic monitoring of at-risk neonates at birth is recom-
mended. Additionally, supportive care including thrombocyte
transfusions, erythrocyte transfusions, erythropoietin, and
recombinant granulocyte colony-stimulating factor administra-
tion are given when needed. However, in general, transient
myelosuppression is mild and does not cause clinical prob-
lems.[37] The same is true for transient myelosuppression-related
immune depression. If transient myelosuppression is resolved
within 10weeks, evenwhenmaternal treatment is continued until
delivery, it is reasonable to expect that in children that are not
exposed to chemotherapy in the last week of gestation, immune
depression would also last for a limited period of time and should
not induce an immune response to inactivated vaccines given
according to the recommended pediatrician schedule. Consistent
with this conclusion, data collected in children born to mothers
who received rituximab to treat hematologic tumors show that
the administration of rituximab is associated with a selective
inhibitory effect on the development of newborn B-cells.[38]
However, the condition is reversible, and B-cell levels return to
normal by 3 to 6 months of age. In the short-term follow-up, no
signiﬁcant infections were identiﬁed, and subsequent immuno-
logical controls revealed an adequate response to standard
vaccinations.[39,40] However, because no substantial data to this
regard is currently available, further studies on the immune
response of children receiving chemotherapy in utero are needed
to exclude the possibility that vaccines (mainly the live attenuated
ones) administered in the 1st days of life may be dangerous. For
example, severe neonatal neutropenia and fatal dissemination of
Bacillus Calmette–Guérin has been reported in children born to
mothers treated with biologicals.[41]
3.3.2. Long-term effects. Several studies have evaluated the
long-term impact of cytotoxic drugs administered during
pregnancy on children. Together with growth and general
development, the main target of most of these studies was the
neurological and psychological development because the central
nervous system is extremely sensitive to these drugs. Mennes
et al,[42] found that children with acute lymphoblastic leukemia,
treated exclusively with chemotherapy, processed information
slower compared to control children, especially when more
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focused precisely. However, contrary to what was feared, the 1st
evaluation of the impact of in utero chemotherapy did not ﬁnd
any neurological problems, even in subjects whose mothers were
treated during the 1st trimester of pregnancy.[34] Subjects were
evaluated during high-school or college and showed normal
neurological and psychological development. Furthermore, the
educational performance of these children corresponded with the
economic and social status of their families, and no learning
disabilities were observed. Similar results were obtained with
other studies including those published by Hahn et al[43] and
Amant et al.[44] Average neuropsychological development was
demonstrated in the great majority of chemotherapy-exposed
children. In addition, when neuropsychological issues were
present, they could be ascribed to prematurity or maternal stress.
Despite these reassuring ﬁndings, the conclusions were not
considered deﬁnitive due to the small sample size of the enrolled
children and the limited follow-up for a number of the cases.
Recently studies have concluded that prenatal exposure to
maternal cancer with or without treatment does not impair the
cognitive development of children. Cardonick et al[18] examined
57 children of mothers diagnosed with cancer while pregnant, 35
of whom had been exposed to chemotherapy in utero. The
children underwent developmental testing and ranged in age
from 18 months to 10.4 years. Based on age, the Bayley Scales of
Infant Development–Third Edition, the Wechsler Preschool and
Primary Scale of Intelligence-Revised, the Wechsler Intelligence
Scale for Children, Third Edition, or the Wechsler Individual
Achievement Test were administered. All parents or primary
caregivers completed the Child Behavior Checklist, which is a
parent questionnaire to assess behavioral and emotional issues.
No signiﬁcant differences were noted in cognitive ability, school
performance, or behavioral competencies between the chemo-
therapy-exposed group and the unexposed children. Cognitive
assessments were within the normal limits in 95% of the cases. In
addition, 71% and 79% of children demonstrated at or above
age equivalency in mathematics and reading scores, respectively,
and 79% of children scored within the normal limits on measures
of behavior.[18] However, older children had signiﬁcantly higher
rates of internalizing behavioral problems. Amant et al[19]
performed a similar study where 96 children (median age, 22
months; range, 12–42 months) were prospectively assessed (byTable 2
Main effects of chemotherapy during pregnancy on embryo and fetu
Period of pregnancy Impact on embryo or fetus Impac
First 4 weeks Either pregnancy loss or no adverse
effect
Not kn
From 4 weeks to the end of 1st
trimester
Malformations in 7%–17% of children
born to mothers receiving a single
drug and 25% in case of combination
therapy
Not kn
Second or 3rd trimester Case reports of reversible fetal heart
toxicity for treatment with
anthracyclines, particularly when




Malformations are as frequent as in
children born to healthy mothers
Myelo
to t
4means of a neurologic examination and the Bayley Scales of
Infant Development) at 18 months, 36 months, or both and
compared with a control group. No signiﬁcant between-group
differences were observed in cognitive development on the basis
of the Bayley score or in subgroup analyses. Prematurity was
correlated with a worse cognitive outcome, but this effect was
independent of cancer treatment.
A 2nd largely studied problem is the potential toxicity of some
drugs, especially anthracyclines and trastuzumab, on fetal heart
development. Interest in the effects of these 2 drugs is based on the
results from several studies. Anthracyclines are well-known for
their cardiotoxic effects that depend on multiple mechanisms,
including oxidative damage, changes in calcium metabolism, and
activation of apoptotic pathways, leading to progressive
deterioration in cardiac function.[45,46] Moreover, anthracycline
toxicity has been shown to be enhanced by the concomitant use of
trastuzumab, a monoclonal antibody that inhibits proliferation
of cells overexpressing human epidermal growth factor receptor
tyrosine kinase, which is used in breast cancers where these cells
are present.[47] Several case reports have described the develop-
ment of fetal heart toxicity after the administration of
anthracycline to pregnant women and have shown these affects
are mostly reversible.[48] Finally, data from pediatric cancer
survivors have shown that anthracycline exposure at a young age
can result in progressive left ventricular dysfunction and clinical
heart failure 10 to 20 years after stopping chemotherapy.[49]
Transplacental passage of anthracyclines has been studied in
vitro and in animals but available data seem to suggest that
delivery to the fetus is relatively poor and umbilical artery sample
concentrations were no higher than 65% of the levels detected in
the mother.[50] However, because the fetal myocardium
signiﬁcantly differs from the adult myocardium, it is theoretically
possible that lower drug concentrations may induce toxic effects
in the fetus. Fortunately, no evidence of cardiac disease was found
in the studies in which the heart function of children exposed to
chemotherapy in utero was evaluated. In the most recent study,
cardiac function was evaluated in 50 children, aged 36 months,
who had been exposed to chemotherapy in utero and 26 of the
cases involved exposure to anthracyclines.[19] A 12-lead
electrocardiography and a detailed echocardiographic examina-
tion were performed. In addition, standard views and measure-
ments were carried out according to the guidelines of thes development.
t on the perinatal period Long-term impact
own Not known
own Not known
m delivery and low birth weight
%)
In general, neuropsychological development is
not affected. When retard is demonstrated,
it is ascribed to prematurity
suppression (1%–43%, according
ime of therapy suspension)
Older children frequently have internalizing
behavioral problems
Progressive left ventricular dysfunction several
years after anthracycline exposure
[4] Salani R, Billingsley C, Crafton S. Cancer and pregnancy: an overview for
Esposito et al. Medicine (2016) 95:38 www.md-journal.comAmerican Society of Cardiology. The results were compared with
47 healthy children matched for age and sex. No structural
abnormalities were detected. All measures of cardiac-chamber
dimension and cardiac wall thickness were within normal ranges,
and there were no between-group differences in ejection fraction,
fractional shortening, or values for global longitudinal strain and
circumferential strain.[19] In particular, there were no differences
in the subjects exposed to anthracyclines compared to the
subjects exposed to other chemotherapy drugs.
Finally, no differences in growth and general development have
been found between exposed children and healthy controls.[19]4. Conclusions
Although studies are limited and results have been obtained on
limited number of patients with no possibility to deﬁne the level
of evidence with a scale, data regarding the ﬁnal outcome of
children who have received in utero chemotherapy seem
reassuring. Table 2 summarizes the main effects of chemotherapy
on embryo and fetus development. Only the administration in the
embryonal stage of conceptus is dangerous and can lead to the
termination of pregnancy.[13] When the disease is diagnosed in
the 2nd or 3rd trimester of gestation or when it is possible to delay
the initiation of chemotherapy beyond the 14th week, the risk of
severe problems for the fetus are low and pregnancy termination
is not needed.
However, these conclusions should be interpreted with
caution because several aspects of chemotherapy in pregnant
woman have not been fully documented. First, many of the
drugs given to pregnant women at the usual dosages show
lower blood concentrations in pregnant women compared
to nonpregnant subjects suggesting that an increased dose is
needed. This increase could expose the mother and the fetus to
subsequent problems. Second, severe neutropenia can occur in
pregnant women with cancer treated with chemotherapy.
Usually this condition is treated with granulocyte colony-
stimulating factor but the effectiveness and safety of this
compound during pregnancy has not deﬁnitively been estab-
lished. Third, any new drugs have to be adequately evaluated
to establish the pharmacokinetic and pharmacodynamic
characteristics in pregnant women during the different periods
of gestation to measure the amount of drug that reaches the
fetus. Finally, studies on immunogenicity, safety, and tolerabili-
ty of routine vaccines administered in the 1st few months of life
are necessary in order to understand whether children born to
mothers with cancer who were treated with chemotherapy
should follow the routine schedule or postpone/anticipate the
administration of some vaccines. Increased knowledge of how
to minimize the risks of chemotherapy can reduce improper
management including unnecessary termination of pregnancy,
delayed maternal treatment, and iatrogenic preterm delivery,
which are frequently applied in the treatment of pregnant cancer
patients.[51]References
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